Unexpectedly catapulted into global fame as a COVID-19 vaccine maker, BioNTech is on the verge of returning to its oncology ...

In a first for the neurotoxin market, Ipsen announced Thursday that its Dysport has hit the goals in two phase 3 trials for the prevention of both episodic and chronic migraines. While AbbVie’s market ...

When launching a drug as big as semaglutide, even as a generic, the market expectations are immense, and any fumble on the ...

Aiming to streamline the compensation process for people claiming harm from COVID-19 vaccines, Robert F. | Aiming to ...

The CARDIO-TTRansform study did not meet its primary endpoint, which centered on reducing cardiovascular deaths or recurrent ...

The comment-seeking period and probe tie back to Sanofi’s marketing for its flu shot for adults ages 60 and over, which is ...

Following a major push by the industry’s heavyweights to simplify their businesses in recent years, Tanabe Pharma is | While ...

Lundbeck’s online promotion of migraine med Vyepti has caught the attention of the FDA, with the agency inking an untitled letter that calls out the company for potentially misleading efficacy claims.

AbbVie’s Allergan Aesthetics, looking to open doors for the next generation of female leaders, welcomed a cohort of young women to its Allergan Medical Institute (AMI) in Orange County, California, ...

When Vera Therapeutics in-licensed atacicept from Merck KGaA about six years ago, patients with IgA nephropathy (IgAN) had no ...

Amid an ongoing expansion of China’s volume-based procurement (VBP) scheme to lower drug costs, the Chinese government has ...